As an additional finding, we observed significant differences in BCR-free rates regarding certain clinical features, independently of the stratum, such as lymph node status (p = 0.0046), stage group (p < 0.0001), and Gleason score (p < 0.0001), in contrast to the preoperative PSA and TNM categories of the EAU, which did not stratify the BCR-free survival of PRAD patients in a significant manner (p = 0.72, p = 0.095, respectively; Supplementary Figure S3). This evidence concerns the gene BCR and prostate adenocarcinoma.